JCR Pharmaceuticals Co., Ltd. JCRRF
3.73 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
3.60 Day range 3.60
3.15 52-week range 4.75
- YTD
- -21.47%
- 1 year
- -17.11%
- Market cap
- 455.12M
- EPS (ttm)
- -0.18
- YTD return
- -21.47%
- 1-year return
- -17.11%
- Volume
- 100
- Avg volume
- 14
- Open
- 3.60
- Previous close
- 3.73
- Day's range
- 3.60 – 3.60
- 52-week range
- 3.15 – 4.75
2Y -0.84 (-18.38%)
News
JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome 
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America 
JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy 
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB 
JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome 
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform 
JCR Pharmaceuticals' Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders 
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting 
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
Your note
Sign in to keep a note on JCRRF — it syncs with the Stock Master app.